Kuvatris Therapeutics Inc Quick Ratio (PXMD) starting from the third quarter 2024 to third quarter 2023, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Kuvatris Therapeutics Inc   (PXMD)

Kuvatris Therapeutics Inc 's Quick Ratio

PXMD's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Kuvatris Therapeutics Inc 's Cash & cash equivalent grew by 37.1 % in the Q3 2024 sequentially, faster than Current Liabilities, this led to improvement in Kuvatris Therapeutics Inc 's Quick Ratio to 0.2, Quick Ratio remained below Kuvatris Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 471 other companies have achieved higher Quick Ratio than Kuvatris Therapeutics Inc in third quarter 2024. While Quick Ratio total ranking in the third quarter 2024 has deteriorated compared to the prior quarter from 3539 to 3578.

Explain Quick Ratio?
How much Cash & cash equivalents PXMD´s has?
What are PXMD´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

PXMD Quick Ratio (Sep 30 2024)
Q3		 (Jun 30 2024)
Q2		 (Mar 31 2024)
Q1		 (Dec 31 2023)
Q4		 (Sep 30 2023)
Q3
Y / Y Current Liabilities Change -31.14 % -13.11 % -31.83 % -7.2 % -8.94 %
Y / Y Cash & cash equivalent Change -61.42 % -89.43 % - 147.68 % -79.28 %
Quick Ratio MRQ 0.2 0.15 1.35 2.62 0.35
PXMD's Total Ranking # 3578 # 3539 # 834 # 716 # 2255
Seq. Current Liabilities Change 6.87 % 75.15 % -32.99 % -45.11 % 34.85 %
Seq. Cash & cash equivalent Change 37.1 % -80.05 % -65.46 % 308.57 % -62.44 %



Quick Ratio third quarter 2024 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 472
Healthcare Sector # 913
Overall Market # 3578


Quick Ratio Statistics
High Average Low
2.62 1.07 0
(Dec 31 2023)   (Jun 30 2022)




Financial Statements
Kuvatris Therapeutics Inc 's Current Liabilities $ 2 Millions Visit PXMD's Balance sheet
Kuvatris Therapeutics Inc 's Cash & cash equivalent $ 0 Millions Visit PXMD's Balance sheet
Source of PXMD's Sales Visit PXMD's Sales by Geography


Cumulative Kuvatris Therapeutics Inc 's Quick Ratio

PXMD's Quick Ratio for the trailling 12 Months

PXMD Quick Ratio

 (Sep 30 2024)
12 Months		 (Jun 30 2024)
12 Months		 (Mar 31 2024)
12 Months		 (Dec 31 2023)
12 Months		 (Sep 30 2023)
12 Months
Y / Y Current Liabilities TTM Growth -21.69 % -13.79 % -44.78 % -53.51 % -47.74 %
Y / Y Cash & cash equivalent TTM Growth 16.04 % -25.82 % 41.29 % 12.82 % 1.8 %
Quick Ratio TTM 0.97 0.93 1.21 0.97 0.65
Total Ranking TTM # 3511 # 3538 # 2170 # 2637 # 3378
Seq. Current Liabilities TTM Growth -12.16 % -3.66 % -6.07 % -1.48 % -3.3 %
Seq. Cash & cash equivalent TTM Growth -9.06 % -26 % 18.21 % 45.86 % -41.86 %

Quick ratio ranking by company, industry and sector >> Back to PXMD Financial Strength Comparisons >> Go to Compare PXMD Quick Ratio to its Competitors

On the trailing twelve months basis Current Liabilities decreased faster than Kuvatris Therapeutics Inc 's average Cash & cash equivalent, this led to increase in in Kuvatris Therapeutics Inc 's Quick Ratio to 0.97, Quick Ratio remained below PXMD average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 451 other companies have achieved higher Quick Ratio than Kuvatris Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 3511, from total ranking during the twelve months ending second quarter 2024 at 3538.

Explain Quick Ratio?
How much Cash & cash equivalents PXMD´s has?
What are PXMD´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 452
Healthcare Sector # 947
Within the Market # 3511


trailing twelve months Quick Ratio Statistics
High Average Low
1.47 1.11 0.72
(Jun 30 2023)   (Mar 31 2023)




Companies with similar Quick Ratio in the quarter ending Sep 30 2024, within Major Pharmaceutical Preparations Industry Quick RatioSep 30 2024 MRQ Cash & cash equivalentSep 30 2024 MRQ Current Liabilities
Akebia Therapeutics Inc   0.52 $ 34.019  Millions$ 65.709  Millions
Durect Corp  0.51 $ 10.376  Millions$ 20.207  Millions
Optinose Inc   0.51 $ 82.497  Millions$ 162.430  Millions
Elanco Animal Health Incorporated  0.50 $ 490.000  Millions$ 988.000  Millions
Merck and Co Inc   0.49 $ 14,593.000  Millions$ 29,586.000  Millions
Vireo Growth Inc.  0.49 $ 7.280  Millions$ 14.802  Millions
Lftd Partners Inc   0.49 $ 3.234  Millions$ 6.598  Millions
Prestige Consumer Healthcare Inc   0.48 $ 51.540  Millions$ 106.906  Millions
Vaccinex Inc   0.47 $ 2.906  Millions$ 6.175  Millions
Bio Green Med Solution Inc   0.47 $ 2.982  Millions$ 6.351  Millions
Scorpius Holdings inc   0.47 $ 4.810  Millions$ 10.336  Millions
Bausch Health Companies Inc   0.46 $ 719.000  Millions$ 1,577.000  Millions
Hyperion Defi inc   0.46 $ 7.188  Millions$ 15.783  Millions
Citius Pharmaceuticals Inc   0.45 $ 3.252  Millions$ 7.156  Millions
Grifols Sa  0.45 $ 1,097.354  Millions$ 2,414.884  Millions
Avid Bioservices Inc   0.45 $ 33.415  Millions$ 74.156  Millions
Biodexa Pharmaceuticals Plc  0.45 $ 2.807  Millions$ 6.303  Millions
Ernexa Therapeutics Inc   0.43 $ 4.264  Millions$ 9.952  Millions
Novartis Ag  0.40 $ 11,592.000  Millions$ 28,692.000  Millions
Stablecoin Development Corporation  0.39 $ 0.776  Millions$ 1.984  Millions
Integrated Biopharma Inc  0.38 $ 2.271  Millions$ 6.029  Millions
Casi Pharmaceuticals inc   0.37 $ 13.468  Millions$ 36.452  Millions
Petros Pharmaceuticals inc   0.36 $ 3.900  Millions$ 10.819  Millions
Ac Immune Sa  0.36 $ 40.003  Millions$ 111.202  Millions
Cytodyn inc   0.36 $ 24.921  Millions$ 69.555  Millions
Bristol myers Squibb Company  0.36 $ 8,094.000  Millions$ 22,638.000  Millions
Intercure Ltd   0.35 $ 21.439  Millions$ 62.070  Millions
Grace Therapeutics Inc  0.34 $ 1.033  Millions$ 3.047  Millions
Catalent Inc   0.34 $ 335.000  Millions$ 998.000  Millions
Aytu Biopharma Inc  0.33 $ 20.108  Millions$ 61.252  Millions

Date modified: 2026-06-22T14:32:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.